Dermata Therapeutics Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Public

  • Employees
  • 9

Employees

  • Stock Symbol
  • DRMA

Stock Symbol

  • Share Price
  • $0.51
  • (As of Friday Closing)

Dermata Therapeutics General Information

Description

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 3525 Del Mar Heights Road
  • Suite 322
  • San Diego, CA 92130
  • United States
+1 (858)
Primary Industry
Other Commercial Products
Other Industries
Pharmaceuticals
Biotechnology
Personal Products
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 3525 Del Mar Heights Road
  • Suite 322
  • San Diego, CA 92130
  • United States
+1 (858)

Dermata Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Dermata Therapeutics Stock Performance

As of 20-Nov-2026, Dermata Therapeutics’s stock price is $0.51. Its current market cap is $2.51M with 4.93M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.51 $0.53 $0.50 - $4.66 $2.51M 4.93M 2.75M -$3.28

Dermata Therapeutics Financials Summary

As of 30-Sep-2026, Dermata Therapeutics has a trailing 12-month revenue of $74.1K.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,038 2,755 (3,389) (4,473)
Revenue 74 0 0 0
EBITDA (9,699) (7,774) (12,513) (8,042)
Net Income (9,498) (7,559) (12,287) (7,795)
Total Assets 6,635 7,864 3,534 7,979
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Dermata Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Dermata Therapeutics‘s full profile, request access.

Request a free trial

Dermata Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. I
Other Commercial Products
San Diego, CA
9 As of 2026

Greenville, SC
 

Randolph, NJ
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Dermata Therapeutics Competitors (26)

One of Dermata Therapeutics’s 26 competitors is Zylo Therapeutics, a Venture Capital-Backed company based in Greenville, SC.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Zylo Therapeutics Venture Capital-Backed Greenville, SC
Spear Pharmaceuticals Formerly PE-Backed Randolph, NJ
Nymox Pharmaceutical Corporation Saint Laurent, Canada
Crescita Therapeutics Corporation Laval, Canada
Aquapharm Biodiscovery Formerly VC-backed Oban, United Kingdom
You’re viewing 5 of 26 competitors. Get the full list »

Dermata Therapeutics Patents

Dermata Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024151612-A1 Compositions for inducing immune responses Inactive 13-Jan-2023
AU-2021394765-A1 Compositions for the treatment of skin conditions Pending 09-Dec-2020
CA-3204909-A1 Compositions for the treatment of skin conditions Pending 09-Dec-2020
EP-4267163-A1 Compositions for the treatment of skin conditions Pending 09-Dec-2020
EP-4267163-A4 Compositions for the treatment of skin conditions Pending 09-Dec-2020 A61K8/987
To view Dermata Therapeutics’s complete patent history, request access »

Dermata Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Dermata Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Dermata Therapeutics‘s full profile, request access.

Request a free trial

Dermata Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Household Products

Industry

Rank

Percentile

Personal Products

Subindustry

Rank

Percentile

To view Dermata Therapeutics’s complete esg history, request access »

Dermata Therapeutics FAQs

  • When was Dermata Therapeutics founded?

    Dermata Therapeutics was founded in 2014.

  • Where is Dermata Therapeutics headquartered?

    Dermata Therapeutics is headquartered in San Diego, CA.

  • What is the size of Dermata Therapeutics?

    Dermata Therapeutics has 9 total employees.

  • What industry is Dermata Therapeutics in?

    Dermata Therapeutics’s primary industry is Other Commercial Products.

  • Is Dermata Therapeutics a private or public company?

    Dermata Therapeutics is a Public company.

  • What is Dermata Therapeutics’s stock symbol?

    The ticker symbol for Dermata Therapeutics is DRMA.

  • What is the current stock price of Dermata Therapeutics?

    As of 20-Nov-2026 the stock price of Dermata Therapeutics is $0.51.

  • What is the current market cap of Dermata Therapeutics?

    The current market capitalization of Dermata Therapeutics is $2.51M.

  • What is Dermata Therapeutics’s current revenue?

    The trailing twelve month revenue for Dermata Therapeutics is $74.1K.

  • Who are Dermata Therapeutics’s competitors?

    Zylo Therapeutics, Spear Pharmaceuticals, Nymox Pharmaceutical, Crescita Therapeutics, and Aquapharm Biodiscovery are some of the 26 competitors of Dermata Therapeutics.

  • What is Dermata Therapeutics’s annual earnings per share (EPS)?

    Dermata Therapeutics’s EPS for 12 months was -$3.28.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process